GDTC CytoMed Therapeutics Ltd: Forward Price-to-Revenue Multiple
CytoMed Therapeutics (GDTC) is optimizing cell product trials through external contractors to minimize internal risks. The projected P/S valuation reflects current market dynamics, where the value 39.90 captures the metric level. Fundamentals rely on NK-therapy developments for oncology and the strong scientific expertise of the Singapore-based management, which effectively allocates resources for early-stage clinical trials.
GDTC (w2.cytomed.sg): analytical breakdowns and indicator data
- stock price and consensus target price:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Total Debt to Capital CytoMed Therapeutics|GDTC - Long-Term Liabilities to Capital|Short-Term Debt to Capital CytoMed Therapeutics Limited|GDTC - Company Aggregate Debt|Debt to Book Value CytoMed Therapeutics Limited|GDTC - Company Long-Term Loans and Borrowings|Company Current Liabilities CytoMed Therapeutics|Quick Ratio w2.cytomed.sg
- business earnings and investment ratios data:
GDTC - Final Profit|Projected Future Earnings CytoMed Therapeutics|GDTC - Market Cap to Earnings|Future Price to Earnings CytoMed Therapeutics Limited|GDTC - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple CytoMed Therapeutics Limited|GDTC - Operating profit EBITDA|Earnings per share for the last twelve months CytoMed Therapeutics|GDTC - Earnings per one share for the last 12 months|Quarterly EPS earnings growth w2.cytomed.sg|GDTC - Earnings per share growth rate in current year|Expected earnings per share growth for next year CytoMed Therapeutics
- revenue and sales details:
Fundamental company valuation:CytoMed (GDTC)
Forward P/S compares the current market value of a business with projected future sales, allowing an investor to assess the extent of the premium paid for expected revenue growth rates. For CytoMed Therapeutics (GDTC), which is currently in the safety validation stage of its bio-platform, the expected price-to-sales ratio serves as an indicator of market confidence in the potential of future pharmaceutical alliances, confirming the fundamental resilience of the development strategy.
Key competitors
BeiGene - Forward Price-to-Revenue Multiple|Halozyme Therapeutics, Inc. (HALO) - Market Cap to Future Revenue Ratio|RVMD: Forward Price-to-Revenue Multiple|Ascentage Pharma Corp - Price to Expected Revenue Ratio|CG Oncology, Inc. (CGON) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio urogen.com (URGN)|Price-to-Projected Revenue Ratio Bicara Therapeutics|Forward Price-to-Revenue Multiple Personalis Inc (PSNL)|Forward P/S Multiple ERAS|DCTH - Market Cap to Future Revenue Ratio|Forward P/S Multiple YMAB (Y-mAbs Therapeutics)|AURA: Market Cap to Projected Revenue|CADL: Forward Price-to-Revenue Multiple|Forward Price to Sales ARAY (Accuray Inc)|SLS (sellaslifesciences.com) - Forward Price-to-Revenue Multiple|ACTU: Price to Expected Revenue Ratio|CTOR (Citius Oncology, Inc.) - Forward P/S Multiple|HURA: Forward Price to Sales|Forward P/S Multiple TARA|FATE - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Aadi Bioscience WHWK|Forward Price to Sales TCRX|Champions Oncology Corp - Forward P/S Multiple|XBIT - Forward P/S Multiple|cel-sci.com (CVM) - Price-to-Projected Revenue Ratio|Future Price to Revenue OSTX (OS Therapies Inc.)|RADX (Radiopharm Theranostics Limited) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Artiva ARTV|Forward Price-to-Revenue Multiple ANL (Adlai Nortye Ltd.)|Forward P/S Multiple verupharma.com (VERU)|Tempest Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio XLO (Xilio Therapeutics Inc)|Enochian BioSciences - Forward P/S Multiple|Market Cap to Expected Sales Ratio Mural Oncology plc MURA|KAPA: Forward P/S Multiple|Forward Price-to-Revenue Multiple OnKure Therapeutics|Price-to-Projected Revenue Ratio Curis Inc.|Apollomics Corp (APLM) - Market Cap to Expected Sales Ratio|Forward P/S Multiple THAR|advanbiomed.com (ADVB) - Projected Price to Revenue|Forward P/S Multiple GNPX (Genprex, Inc.)|CLDI: Market Cap to Projected Revenue|SBFM: Forward Price-to-Revenue Multiple|Xenetic Biosciences - Price to Expected Revenue Ratio|SLRX: Forward P/S Multiple|Forward Price-to-Revenue Multiple Kitov Pharma|AONC (American Oncology Network Inc) - Forward P/S Multiple|Forward Price-to-Revenue Multiple beigene.com (BGNE)|Forward P/S Multiple CKPT|Forward P/S Multiple elevationoncology.com (ELEV)|Price-to-Projected Revenue Ratio iCAD ICAD|IKNA: Market Cap to Projected Revenue|Notable Labs, Ltd. - Forward P/S Multiple|Viracta Therapeutics (VIRX) - Forward Price-to-Revenue Multiple|MOR: Forward P/S Multiple|Market Cap to Future Revenue Ratio NAYA Biosciences Inc (NAYA)|Price-to-Projected Revenue Ratio Ascentage Pharma Group Ltd
